FY2029 Earnings Estimate for MIST Issued By HC Wainwright

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) – Equities research analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for Milestone Pharmaceuticals in a research report issued to clients and investors on Monday, January 27th. HC Wainwright analyst P. Trucchio forecasts that the company will post earnings per share of $1.86 for the year. HC Wainwright has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for Milestone Pharmaceuticals’ current full-year earnings is ($0.62) per share.

Milestone Pharmaceuticals Stock Down 1.5 %

NASDAQ MIST opened at $2.02 on Tuesday. The company has a debt-to-equity ratio of 2.18, a quick ratio of 15.40 and a current ratio of 15.40. The business has a fifty day moving average price of $1.96 and a 200 day moving average price of $1.66. Milestone Pharmaceuticals has a one year low of $1.12 and a one year high of $2.75. The company has a market cap of $107.73 million, a P/E ratio of -2.49 and a beta of 1.78.

Milestone Pharmaceuticals (NASDAQ:MIST) last posted its earnings results on Tuesday, November 12th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.04.

Institutional Investors Weigh In On Milestone Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Valeo Financial Advisors LLC grew its holdings in shares of Milestone Pharmaceuticals by 100.0% in the third quarter. Valeo Financial Advisors LLC now owns 20,000 shares of the company’s stock valued at $30,000 after purchasing an additional 10,000 shares in the last quarter. PVG Asset Management Corp acquired a new position in shares of Milestone Pharmaceuticals in the third quarter valued at approximately $46,000. Atria Investments Inc increased its stake in shares of Milestone Pharmaceuticals by 44.4% during the third quarter. Atria Investments Inc now owns 40,421 shares of the company’s stock worth $61,000 after acquiring an additional 12,430 shares during the period. Finally, BML Capital Management LLC boosted its position in shares of Milestone Pharmaceuticals by 3.0% during the 3rd quarter. BML Capital Management LLC now owns 1,136,091 shares of the company’s stock worth $1,727,000 after purchasing an additional 33,196 shares in the last quarter. Hedge funds and other institutional investors own 86.18% of the company’s stock.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.